close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Novartis Leads Learning Revolution in China

BASEL, Switzerland, March 7, 2007--For Novartis, learning programs remain an important tactic to take China's workforce up to speed in skill sets and to retain top managers, especially when the company is planning further investments.

"The investments in clinical areas must be matched by a concurrent investment in development," said Head Global Learning Frank Waltmann. "Several challenges remain in this area. Novartis will set the pace for meeting them within the region by leveraging our development strengths and connecting to our Chinese staff in ways that will help them commit to the company."


The paradox: Shortage among plenty

China's employee pool is different than anywhere else in the world. On one hand, the country produced 3.1 million university graduates in 2005, while the U.S. produced 1.3 million. However, fewer than 10 percent of these graduates in China have the skills to work for a foreign company. Moreover, employers in the region are beginning to compete more vociferously for these 10 percent, especially for entry-level, white-collar workers. And as mentioned, mid-to-senior level managers are scarce, and don't tend to stay on board very long, either.


Importing managers not as effective In the past, multinationals relied on expatriate managers from Europe, North America and other highly developed Asian countries to oversee their operations in China. At the same time, 40 percent of these companies have difficulty filling these roles. Local firms are now competing for local talent, as well, causing a "reverse brain drain" in the market. And the situation will only get worse: In 10 years, experts predict that China will need 75,000 managers with international experience. As of today, it only has 5,000 people who could fulfil these roles.


"Leadership has become much more important in China. Not only in top management, but at every level throughout the company," said Novartis CPO Head China James Liu. "We're counting on powerful Learning programs to help us meet these leadership goals."


Novartis needs managers with industry-specific skills. Therefore, business needs will dictate curriculum focus to a very high degree. "Novartis has significant investments in China for expanded clinical trials; chemical analytical development and production; and more," said Waltmann. "How will we possibility hope to meet our goals there unless we embark on an ambitious program to attract and retain talent in China?"


Novartis explores new possibilities for talent management Novartis already uses a systematic approach to developing associates worldwide. It organizes these activities in four main categories:


a.. Internal focus: Growing leaders from within and filling 70 percent of internal open positions with internal associates b.. Commitment to codified development planning: Ensuring that each associate has a development plan c.. Managing development on the front line: Ensuring that each associate has a minimum of two career and development discussions every year

The Novartis development structure also allows employees to hone leadership skills while they are fulfilling current roles. Its leadership standards and behaviours, functional competency models and talent management processes are embedded in both on-boarding training and during ongoing performance development processes for each employee. Accelerated development programs, mentoring options and other special programs also help create a culture of continuous learning. This will be very important in China because surveys show that Chinese managers often single out inadequate career development as one of the key reasons for their departure. Novartis will meet this need by focusing on internal talent within the region in three key areas:


· Develop them through traditional, but world class training and enhanced on-the-job training

· Deploy them in stretch assignments and provide a clearly defined career path

· Connect them to their peers and other professionals


In addition, Novartis will implement several different career tracks and offer development goals and training opportunities in concert with these. A project management track, a management track and a scientific track will fulfil the goals of the Chinese workforce. These three areas will meet the gaps in the talent pool in the region. They address the issues that Novartis has with getting entry-level workers for scientific endeavours and research. They also address the needs of these same workers for leadership development, beginning with the most basic management skills for people and for projects. Starting with these new hires, it can ensure that the pipeline of talented people does not run dry.


"Throughout, a comprehensive awareness and communication program will help them become aware of, and then take advantage of, the investment we continue to make in their development and learning. As they go from entry level to management to leadership, we hope this will make them much less likely to follow the 8-12 month pattern of leaving," said Waltmann.


The China Leadership Development Centre Novartis will fulfil these development goals and, by extension, talent goals, through two kinds of programs offered through a single entity: The Novartis China Leadership Development Centre. The Centre encompasses these goals using both regional and global learning offerings. First, the BiMBA program launched to great effect last year. It brought 46 high potential Chinese staff members through a mini-MBA course over 18 months. Attendees worked in English in four-day-at-a-time modules over a 4-8 week timeframe. The Learning Centre also offers tailored, localized corporate programs to develop leadership, marketing excellence, leadership of global projects and frontline management skills.


"We were careful to adapt our global programs and make them relevant to the challenges Chinese managers face in their markets and the leadership and project-specific issues they face, as well. It's not a one-size fits all solution," Waltmann said.


Connected leaders stay connected to the company Novartis is also well positioned to build talent in the region because it is one of the most localized companies. "Compared to other multinationals, their presidents, VPs and even directors come from Europe or America or Singapore. About 99 percent of Novartis' staff is Chinese," said Liu.


This situation poses issues with the language gap, but also allows Novartis to build another effective strategy for managing talent in the region: Communicating to connect. The team is committed to keeping employees up-to-date on the latest business developments through monthly lunches with representatives from senior management and staff. This helps close the "what's in it for me?" gaps that cause people to jump from company to company. It invests Chinese staff members in wider global strategies and allows them to feel like contributing members of a team. They are not being expected to follow directives from a disembodied voice: They will meet global leadership one-on-one.


All regions and offices will be included when it comes to strategy and building consensus behind broad company goals. Novartis is now building an embedded communications pipeline that will reach each regional office.


Novartis has also ensured Chinese staff takes longer-term business trips to global headquarters in Basel and to other major sites. This will help them expand their network and integrate more completely into the corporate culture.


"We want our Chinese leaders to become more effective in China, of course. But we also want them to become more effective in the global Novartis organisation. This sense of community and connectedness can be built into our culture in China via a coherent learning strategy. We also have cohesive development goals for every single person who works there. In that way, we can watch our learning goals meet talent goals that will drive the business in a very growth-oriented region. We're well positioned to get great results," Waltmann concludes.


CONTACT:
Leslie Komet Ausburn
Berry Ecke Associates
210.479.7255 or lausburn@satx.rr.com

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...